AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer
TVNIM-AFU
1 other identifier
observational
8,000
1 country
44
Brief Summary
The AFU has set itself the task of setting up a register of medical practices in order to define possible improvements in the therapeutic management and follow-up of NMIBC. In order to obtain representative data, all urologists who are members of the AFU may be invited to include their patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2023
Longer than P75 for all trials
44 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 4, 2021
CompletedFirst Posted
Study publicly available on registry
August 12, 2021
CompletedStudy Start
First participant enrolled
February 21, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2034
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 1, 2035
April 30, 2026
April 1, 2026
11 years
August 4, 2021
April 24, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Recurrence-Free Survival
New bladder cancer (Whether NMIBC or MIBC).
5 years
Performance of urine tests (biomarkers)
To evaluate the diagnostic performance of urine tests (biomarkers) available in France, and providing a binary result (positive: probable presence of a tumor recurrence; negative: probable absence of a tumor recurrence) correlated to the result of the bladder endoscopy performed as part of the routine care for the follow-up of NMIBC: determination of the negative and positive predictive values of biomarkers.
5 years
Secondary Outcomes (1)
Progression-Free Survival
5 years
Eligibility Criteria
Patient being monitored for a non-muscle-invasive bladder tumor and having undergone a urinary test (biomarker) prior to their resection (biopsy) diagnosis or recurrence
You may qualify if:
- Patient being monitored for a non-muscle-invasive bladder tumor and having undergone a urinary test (biomarker) prior to their resection (biopsy) diagnosis or recurrence,
- AND adult (equal to or \> 18 years old),
- AND affiliated with a social security scheme in France,
- AND whose monitoring will be carried out at the recruiting center.
You may not qualify if:
- Patient being monitored for a non-urothelial bladder tumor
- Patient refusing follow-up
- Opposition to participation in the study
- Adult protected by law
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (44)
Hopital Prive de Provence
Aix-en-Provence, 13080, France
CHU Angers
Angers, 49933, France
Hopital Privé Arras les Bonnettes
Arras, 62000, France
Centre hospitalier Privé Montgradé
Aubergenville, 78410, France
Centre Hospitalier Beauvais Simone Veil
Beauvais, France
CHU Caen
Caen, France
Hôpital Privé de Sévigné
Cesson-Sévigné, France
Clinique des Cèdres
Cornebarrieu, France
GH Eaubonne-Montmorency Hopital Simone Veil
Eaubonne, 95602, France
CHD Vendée
La Roche-sur-Yon, France
CHU Kremlin Bicêtre APHP
Le Kremlin-Bicêtre, France
Pôle Santé Sud
Le Mans, 72016, France
Clinique Bon Secours
Le Puy-en-Velay, France
Hopital Franco-Britannique Cognac Jay
Levallois-Perret, France
Clinique Mutualiste de la porte de l'Orient
Lorient, 56100, France
Clinique de la Sauvegarde
Lyon, France
Hopital Edouard Heriot
Lyon, France
Hopital Lyon Sud
Lyon, France
Clinique de la Région Mantaise
Mantes-la-Jolie, France
Hôpital privé Européen - Marseille
Marseille, France
Centre Hospitalier Martigues
Martigues, France
Grand Hôpital de l'Est-Francilien
Meaux, France
Clinique Beau Soleil
Montpellier, France
CHU Nimes
Nîmes, France
CH Saint-Louis APHP
Paris, 75010, France
GH Paris Saint Joseph
Paris, 75014, France
Hôpital Européen Georges Pompidou APHP
Paris, 75015, France
GH Pitié-Salpêtrière APHP
Paris, France
CH Perpignan
Perpignan, 66000, France
GHT Novo - CH René Dubos Pontoise
Pontoise, France
Centre Hospitalier Annecy Genevois
Pringy, France
Clinique la Croix du Sud
Quint-Fonsegrives, France
Clinique Mathilde
Rouen, France
Clinique Saint Hilaire
Rouen, France
Clinique Pasteur
Royan, France
Clinique Saint Germain en laye
Saint-Germain-en-Laye, France
Hopital Privé Saint Grégoire
Saint-Grégoire, 35760, France
Clinique Santé Atlantique
Saint-Herblain, 44800, France
Clinique de l'Union
Saint-Jean, France
Polyclinique de l'Europe
Saint-Nazaire, 44600, France
Centre Hospitalier de Saintonge
Saintes, 17100, France
Hopital Foch
Suresnes, France
Polyclinique de l'Ormeau
Tarbes, 65000, France
Clinique Pasteur
Toulouse, 31076, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 4, 2021
First Posted
August 12, 2021
Study Start
February 21, 2023
Primary Completion (Estimated)
February 1, 2034
Study Completion (Estimated)
February 1, 2035
Last Updated
April 30, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share